Published in Law and Health Weekly, March 18th, 2006
The indenture governing the notes requires Ivax to make the offer as a result of the merger of Ivax with and into a wholly owned subsidiary of Teva and the related replacement of the board of Directors of Ivax.
Ivax is offering to purchase the notes for cash at a purchase price, per $1,000 principal amount, equal to 100% of the principal amount, together with $17.88 per $1,000 principal amount, representing accrued and unpaid cash interest to, but...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.